Contents

Issue 142 • May 2024

In association with

Cover Story

Anticipation rises for RSV rollout as positive data emerges

Feature

Molecular glues are the latest craze in pharma research, but what are they?

Interview

BARDA wants to back tech that can combat multiple infections, says director

In Depth

Anticipation rises for RSV rollout as positive data emerges

Continuous monitoring expands aseptic knowledge and data in real time

Molecular glues are the latest craze in pharma research, but what are they?

Using pharmacovigilance to turn reactive investigation into active discovery

Lenmeldy becomes world’s most expensive drug

Q&A: BARDA wants to back tech that can combat multiple infections, says chief

Briefing

News in Numbers

Latest News

Latest Deals

Project Updates

Trends & Insight

05/14/2024 08:51:51
  • Home | Anticipation rises for RSV rollout as positive data emerges
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • phasetwo
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Trends & Insight
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • Avenga Company Insight
  • In Depth
  • Anticipation rises for RSV rollout as positive data emerges
  • Continuous monitoring expands aseptic knowledge and data in real time
  • Molecular glues are the latest craze in pharma research, but what are they?
  • Using pharmacovigilance to turn reactive investigation into active discovery
  • Lenmeldy becomes world’s most expensive drug
  • Q&A: BARDA wants to back tech that can combat multiple infections, says director
  • Sponsored Supplements
  • ZETA
  • Nipro
  • Listings
  • Events
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
04/18/2024 00:00:00